| Date Filed | Type | Description |
| 08/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits... |
| 08/03/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 07/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/20/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/18/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/18/2023 |
10-K
| Annual Report for the period ended March 31, 2023 |
| 05/18/2023 |
8-K
| Quarterly results |
| 02/27/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 10% stake in Replimune Group, Inc. |
| 02/14/2023 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 9.2% stake in REPLIMUNE GROUP INC |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
10-Q
| Quarterly Report for the period ended December 31, 2022 |
| 02/09/2023 |
8-K
| Quarterly results |
| 02/03/2023 |
SC 13G
| BlackRock Inc. reports a 5.5% stake in Replimune Group, Inc |
| 01/04/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer Woburn, MA, January 4, 2023 – Replimune Group, Inc. , a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies , announced today the appointment of Christopher Sarchi as Replimune’ s Chief Commercial Officer and the appointment of Sushil Patel, Ph.D., previously Replimune’ s Chief Commercial Officer, to a newly formed position of Chief Strategy Officer, effective immediately. “These leadership appointments provide broad strategic and operational commercial acumen as we ramp up our commercial planning ahead of the potential 2024 launch of RP1,” said Philip Astley-Sparke, Chie..." |
|
| 12/12/2022 |
8-K
| Quarterly results |
| 12/12/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 12/07/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 12/07/2022 |
8-K
| Quarterly results |
| 12/06/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 11/18/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/03/2022 |
8-K
| Quarterly results |
| 10/07/2022 |
8-K
| Quarterly results |
| 09/14/2022 |
SC 13D/A
| Atlas Venture Fund X, L.P. reports a 4.4% stake in REPLIMUNE GROUP, INC. |
| 09/08/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/04/2022 |
8-K
| Quarterly results |
| 07/28/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
|